Eli Lilly (LLY) director buys 233 shares at $1,021 on Form 4
Eli Lilly and Company director reports stock purchase.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Eli Lilly and Company director reports stock purchase. A reporting person serving as a director of Eli Lilly & Co (LLY) acquired 233.271 shares of common stock on 11/17/2025 at a price of $1,021.7 per share, according to a Form 4 filing. Following this transaction, the director beneficially owns 304.271 shares of Eli Lilly common stock in direct ownership.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 233.271 | $1,021.70 | $238K |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Eli Lilly (LLY) report on this Form 4?
The Form 4 reports that a director of Eli Lilly & Co (LLY) acquired 233.271 shares of common stock on 11/17/2025.
What is the role of the reporting person in Eli Lilly (LLY)?
The reporting person is identified as a Director of Eli Lilly & Co (LLY).
Is this Eli Lilly (LLY) Form 4 filed by one or multiple reporting persons?
The Form 4 is indicated as being filed by one reporting person.
What is the date of the earliest transaction reported in this Eli Lilly (LLY) Form 4?
The earliest transaction date reported is 11/17/2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.